HC Wainwright Lowers Earnings Estimates for Pharming Group

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) – Analysts at HC Wainwright dropped their Q3 2026 earnings estimates for shares of Pharming Group in a report issued on Thursday, July 30th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of $0.20 for the quarter, down from their previous forecast of $0.30. The consensus estimate for Pharming Group’s current full-year earnings is $0.20 per share. HC Wainwright also issued estimates for Pharming Group’s FY2026 earnings at $0.40 EPS and FY2027 earnings at $0.50 EPS.

Several other brokerages have also issued reports on PHAR. Weiss Ratings lowered Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wall Street Zen downgraded Pharming Group from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Zacks Research lowered Pharming Group from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Canaccord Genuity Group boosted their price objective on Pharming Group from $37.00 to $38.00 and gave the company a “buy” rating in a research report on Monday. Finally, Oppenheimer restated an “outperform” rating on shares of Pharming Group in a research report on Thursday, July 30th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $38.67.

Pharming Group Stock Up 4.5%

NASDAQ PHAR opened at $10.26 on Monday. Pharming Group has a twelve month low of $9.62 and a twelve month high of $21.34. The stock has a market cap of $726.20 million, a PE ratio of 85.50 and a beta of -0.01. The firm has a 50-day simple moving average of $12.90 and a 200 day simple moving average of $15.05. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.06 and a current ratio of 3.01.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.04). The company had revenue of $90.20 million for the quarter, compared to the consensus estimate of $99.52 million. Pharming Group had a return on equity of 3.40% and a net margin of 2.51%.

Institutional Trading of Pharming Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC acquired a new position in Pharming Group in the second quarter worth about $32,000. SmartHarvest Portfolios LLC acquired a new stake in Pharming Group during the fourth quarter valued at approximately $224,000. Millennium Management LLC acquired a new stake in Pharming Group during the fourth quarter valued at approximately $360,000. Finally, NewEdge Advisors LLC grew its stake in shares of Pharming Group by 11,310.3% in the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares during the period. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.